According to Nymox Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -3.33333. At the end of 2022 the company had a P/E ratio of -4.00.
Year | P/E ratio | Change |
---|---|---|
2022 | -4.00 | -53.85% |
2021 | -8.67 | -40.59% |
2020 | -14.6 | 32.62% |
2019 | -11.0 | 59.54% |
2018 | -6.89 | -45.68% |
2017 | -12.7 | 33.1% |
2016 | -9.54 | 36.64% |
2015 | -6.98 | 109.36% |
2014 | -3.33 | -92.86% |
2013 | -46.7 | 56.55% |
2012 | -29.8 | 12.48% |
2011 | -26.5 | -24.67% |
2010 | -35.2 | 23.51% |
2009 | -28.5 | 34.01% |
2008 | -21.3 | -33.58% |
2007 | -32.0 | 69.68% |
2006 | -18.9 | 25.91% |
2005 | -15.0 | -14.6% |
2004 | -17.6 | -0.97% |
2003 | -17.7 | -17.72% |
2002 | -21.5 | -22.7% |
2001 | -27.9 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 11.2 | -436.93% | ๐บ๐ธ USA |
Pfizer PFE | 14.9 | -547.58% | ๐บ๐ธ USA |
Abbott Laboratories ABT | 38.2 | -1,247.23% | ๐บ๐ธ USA |
Eli Lilly LLY | 143 | -4,398.67% | ๐บ๐ธ USA |
Quest Diagnostics
DGX | 19.7 | -690.72% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.